Panel: Reimagining Preclinical: Innovation Under Pressure

Session details:

The FDA’s push to phase out animal testing has collided with mounting pressure to de-risk early-stage development, creating a perfect storm of regulatory and scientific challenges. As federal R&D funding faces unprecedented cuts, companies must fundamentally reimagine how breakthrough therapies reach patients. This discussion will explore the emerging technologies and partnerships reshaping preclinical development in an era of constrained resources and evolving standards.